A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Neeta Somaiah,Sant P. Chawla,Matthew S. Block,John C. Morris,Khanh Do,Joseph Kim,Mihaela Druta,K. K. Sankhala,Patrick Hwu,Robin L. Jones,Sacha Gnjatic,Seunghee Kim-Schulze,Kevin Tuballes,Mahlet Yishak,Hailing Lu,Adam J. Yakovich,Jan ter Meulen,Michael Chen,Richard T. Kenney,Chet Bohac,Seth M. Pollack

A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

2020

Preclinical data suggest that a “prime-boost” vaccine regimen using a target-expressing lentiviral vector for priming, followed by a recombinant protein boost, may be effective against cancer; howe...

Keywords:

NY-ESO-1
Immunogenicity
Regimen
Oncology
Cancer
Immunotherapy
Medicine
prime boost
Internal medicine
Lentivirus
Viral vector

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations